- CRISPR-based microbial engineering, leveraging precise gene editing tools such as CRISPR/Cas systems, is a critical technology revolutionizing fields such as industrial biotechnology, agriculture, and therapeutics due to its unparalleled accuracy, efficiency, and cost-effectiveness in modifying microbial genomes
- The escalating demand for CRISPR-based microbial engineering is primarily fueled by the increasing prevalence of genetic disorders, rising investments in genomics and biotechnology research, and the growing need for enhanced productivity and novel products in biomanufacturing and agriculture
- North America dominates the CRISPR-based microbial engineering market with the largest revenue share of 42.5% in 2024, characterized by robust R&D infrastructure, significant government and private funding for life sciences, and the strong presence of key biotechnology and pharmaceutical companies, with the U.S. being a major hub for CRISPR innovations and clinical trials
- Asia-Pacific is expected to be the fastest growing region in the CRISPR-Based microbial engineering market during the forecast period with a CAGR of 21.3% due to increasing government support for biotechnology, rapid expansion of the biopharmaceutical sector, and rising adoption of advanced gene editing technologies in countries
- Therapeutic applications dominates the CRISPR-Based microbial engineering market with a market share of 64.55% in 2024, driven by its immense potential of CRISPR to develop gene therapies for various diseases, engineer microbial vectors for drug delivery, and combat antibiotic resistance
